Charles River is a global leader in providing products and services that support pharmaceutical and biotechnology companies, government agencies, and academic institutions in accelerating research and drug development. With a presence in over 150 facilities across 21 countries, Charles River has a longstanding history of contributing to the advancement of therapeutics. Since 2020, the company has played a role in supporting over 80% of the pharmaceuticals approved by the U.S. Food and Drug Administration (FDA).
As part of its comprehensive service offerings, Charles River operates a specialised division focused on microbial testing for Quality Control.
Charles River’s Quality Control division will be hosting a series of seminars titled "Let’s Rethink the Future of Quality Control." SeerPharma is honoured to be invited as a guest speaker at these events, which will take place in:
- Sydney – Wednesday, 26th March
- Melbourne – Thursday, 3rd April
These seminars will explore innovative strategies to enhance Quality Control, with discussions on optimising data-driven decision-making, improving efficiency, and fostering sustainable workflows.
The sessions will be led by Charles River’s technical experts, Alan Hoffmeister and Yong Jian Lee, with Michelle Peake, Senior Consultant at SeerPharma, presenting on Contamination Control Strategy in the context of the latest revision to Annex 1 of the PIC/S Guide to GMP.
Event Details & Registration
Don't miss this opportunity to gain valuable insights into the future of Quality Control in the pharmaceutical industry.
Collaborating and sharing our insights at industry-leading events such as these is just another way we further our mission to “Advance Quality and GMP Best Practices across the APAC region”.
